Evidence map›Paper›PMID 30203514›Full record

ArticleJournal of clinical hypertension (Greenwich, Conn.)2018

Kidney protective effects of baroreflex activation therapy in patients with resistant hypertension.

Manuel Wallbach, Petra Zürbig, Hassan Dihazi, Gerhard A Müller, Rolf Wachter, Joachim Beige, Michael J Koziolek, Harald Mischak

Open access · bronzeAbstract read
In one paragraph

Article in Journal of clinical hypertension (Greenwich, Conn.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Successful baroreflex activation therapy in a case of therapy-resistant renovascular hypertension.Clinical research in cardiology : official journal of the German Cardiac Society · 2023
    Article
  3. Impact of medication adherence on the efficacy of Baroreflex activation therapy.Journal of clinical hypertension (Greenwich, Conn.) · 2022
    Article
  4. Review
  5. Article
  6. Implant-Mediated Therapy of Arterial Hypertension.Current hypertension reports · 2020
    Review
  7. One approach to circulation and blood flow in the critical care unit.World journal of critical care medicine · 2019
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Manuel WallbachDepartment of Nephrology & Rheumatology, University Medical Center Göttingen, Göttingen, Germany.ORCID 0000-0002-1162-4682
Petra ZürbigMosaiques Diagnostics GmbH, Hannover, Germany.
Hassan DihaziDepartment of Nephrology & Rheumatology, University Medical Center Göttingen, Göttingen, Germany.
Gerhard A MüllerDepartment of Nephrology & Rheumatology, University Medical Center Göttingen, Göttingen, Germany.
Rolf WachterDepartment of Cardiology & Pneumology, University Medical Center Göttingen, Göttingen, Germany.
Joachim BeigeDepartment of Nephrology/KfH Renal Unit, Hospital Sankt Georg, Leipzig, Germany.
Michael J KoziolekDepartment of Nephrology & Rheumatology, University Medical Center Göttingen, Göttingen, Germany.
Harald MischakMosaiques Diagnostics GmbH, Hannover, Germany.
Universitätsmedizin Göttingen · DEMosaiques Diagnostics and Therapeutics (Germany) · DEKlinikum St. Georg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Baroreflex activation therapy (BAT) is approved for the treatment of resistant hypertension. In addition to blood pressure (BP) reduction, pilot studies suggested several organoprotective effects of BAT. Thirty-two patients with resistant hypertension were prospectively treated with BAT. Besides office BP and 24-hour ambulatory BP (ABP) measurements, detection of a urinary proteome-based classifier (CKD273), which has been shown to predict chronic kidney disease (CKD) progression, was carried out at baseline and after 6 months of BAT. Office BP significantly decreased from 170 ± 25/90 ± 18 to 149 ± 29/82 ± 18 mm Hg. Analysis of CKD273 score and eGFR with CKD-EPI equation at baseline revealed strong correlation (r = 0.568, P < 0.001). After 6 months of BAT, there was no significant change in CKD273 score (-0.061 [95% CI: -0.262 to 0.140], P = 0.601). However, by stratification of the data regarding ABP response, there was a statistically significant (P = 0.0113) reduction in the CKD273 score from a mean of 0.161 [95% CI: -0.093 to 0.414] to -0.346 [95% CI: -0.632 to -0.060] after BAT in patients with systolic ABP decrease of ≥5 mm Hg. These data emphasized potential nephroprotective effects of BAT in patients with sufficient BP response.

Indexed as

AgedAntihypertensive AgentsBaroreflexBlood Pressure Monitoring, AmbulatoryElectric Stimulation TherapyElectrodes, ImplantedFemaleGlomerular Filtration RateHumansHypertensionKidneyMaleMiddle AgedPressoreceptorsProspective StudiesProteomeAntihypertensive AgentsProteomebaroreflex activation therapyCKD273resistant hypertensionurinary proteomic

Identifiers

PMID30203514
PMCPMC8030795
OpenAlexW2889926005

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.